Veracyte

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Veracyte reports record Q4 revenue and strategic growth initiatives

Veracyte's Q4 performance reflects strong financials and product advancements, positioning the company for continued growth.
While facing challenges in cost management and operational transitions, Veracyte remains proactive in addressing market demands.
Opportunities for revenue growth and market expansion through new product developments and reimbursement progress are key focus areas.
Overall, Veracyte's strategic initiatives and market positioning suggest a promising outlook for future success.

Veracyte reports robust Q1 earnings, eyes global expansion opportunities

Veracyte's strong Q1 performance was driven by Afirma and Decipher tests, despite challenges in the biopharma business.
The company's focus on global expansion, product enhancement, and evidence generation positions it well for future growth.
Challenges in margins and customer spending require strategic adjustments, but Veracyte remains optimistic about its investment levels.
ESG efforts and commitment to patient outcomes underscore Veracyte's dedication to transforming healthcare and stakeholder value.

Veracyte reports strong Q2 earnings, raises 2023 revenue outlook

Veracyte's Q2 performance reflects robust revenue growth, operational efficiency, and increased market confidence.
While facing challenges in the biopharma segment and manufacturing transitions, the company is well-positioned to capitalize on market opportunities.
With raised revenue projections, strong product performance, and strategic focus areas, Veracyte is poised for continued growth and market expansion.

Veracyte (VCYT) reports robust Q3 performance and eyes market expansion

Veracyte (VCYT) delivered strong financial results in Q3 2023, driven by core testing business growth and strategic partnerships.
Despite supply chain challenges, the company remains focused on market expansion, operational optimization, and cash flow generation.
With a positive outlook for 2024 and a focus on evidence generation and market penetration, Veracyte is poised for continued growth and transformation in cancer care.

Veracyte reports record 2023 revenue, eyes market expansion in 2024

Veracyte's strong 2023 performance sets the stage for continued growth in 2024.
Balancing short-term challenges with long-term opportunities for market expansion.
Strategic acquisitions and product developments position Veracyte well in evolving markets.
Maintaining financial guidance and operational focus key to sustained success.

Veracyte's Q1 2024 earnings call showcased strong revenue growth driven by Decipher Prostate and Afirma.
The company raised total revenue guidance for 2024 and highlighted interest from biopharma in data projects.
While facing challenges like FDA LDT regulation, Veracyte remains focused on existing growth drivers and global expansion.
Excitement surrounds the company's growth trajectory and opportunities in Decipher, MRD testing, and new cancer challenges.

Veracyte reports stellar Q2 results, eyes revenue growth opportunities

Veracyte's Q2 2024 performance reflects robust revenue growth, driven by strong testing revenue and strategic initiatives focused on market expansion and innovation.
Despite facing seasonal revenue fluctuations, the company remains optimistic about achieving its raised revenue guidance for 2024, underpinned by the growth in testing business.
The emphasis on profitability, cash generation, and revenue growth through Decipher and Afirma positions Veracyte well for sustained financial success and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the fourth quarter and full-year 2022 after the close of market on Wednesday, February 22, 2023. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.

Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Veracyte, Inc. (Nasdaq: VCYT) today announced that six abstracts highlighting new data focused on the company's Decipher urologic cancer testing offerings will be presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium, taking place in San Francisco, Calif. and online, February 16-18, 2023.

Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Veracyte, Inc. (Nasdaq: VCYT) today announced that data published in Frontiers in Endocrinology provide new insights into the frequency and risk of malignancy (ROM) associated with thyroid stimulating hormone receptor (TSHR) mutations in indeterminate thyroid nodules. The findings, which were derived from analyses of Veracyte's comprehensive thyroid nodule database of whole transcriptome sequencing, suggest that the use of Afirma testing could help inform diagnoses and personalized treatment decisions for patients with thyroid nodules.

Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules

Exact Sciences

As cancer screenings are becoming covered more often, both companies stand to gain.

Better Long-Term Buy in 2023: Exact Sciences or Veracyte?

This genomic test maker's stock was beaten down in 2022. But it could be heading for a rebound this year.

This Small-Cap Stock Is a No-Brainer Buy

Neovasc

Tactile Systems

Here we discuss three medical instruments stocks - TCMD, VCYT and NVCN - that have started to recover in the past few months after declining for the major part of 2022.

3 Medical Instruments Stocks on Recovery Path After Dismal 2022

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Veracyte, Inc. (Nasdaq: VCYT) today announced that findings demonstrating the strong real-world performance of the Afirma Genomic Sequencing Classifier (GSC) were published in The Journal of Clinical Endocrinology & Metabolism (JCEM). The data, from a meta-analysis of 13 independent studies, show that the Afirma GSC can accurately rule out thyroid cancer in patients with indeterminate thyroid nodules (ITNs) and that, when the test identifies a nodule as suspicious, the patient's risk of malignancy is consistent with, and higher than, that reported in the test's original clinical validation (CV) study.

Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte's Afirma GSC in Thyroid Cancer Diagnosis

Veracyte (VCYT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Veracyte (VCYT) a New Buy Stock

VCYT exceeded investors' expectations, coupling solid revenue growth with improved profitability. Unique international exposure offers revenue tailwinds as Europe accelerates gene diagnostic testing adoption.

Veracyte: Sustainable Rally Supported By Spectacular Execution In Q3

Veracyte (VCYT) delivered earnings and revenue surprises of 50% and 12.82%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Veracyte (VCYT) Reports Q3 Loss, Tops Revenue Estimates

Veracyte, Inc. (NASDAQ:VCYT ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 AM ET Company Participants Shayla Gorman - Director of Investor Relations Marc Stapley - Chief Executive Officer Rebecca Chambers - Executive Vice President and Chief Financial Officer Tina Nova - President, U.S. CLIA Business Conference Call Participants Jacob Johnson - Stephens Griffin Soriano - William Blair Mike Matson - Needham & Company Hugo Leo - Morgan Stanley David Hein - Goldman Sachs Operator Good day, and thank you for standing by. Welcome to the Veracyte Third Quarter 2022 Financial Results Conference Call.

Veracyte, Inc. (VCYT) Q3 2022 Earnings Call Transcript

Veracyte Announces Third Quarter 2022 Financial Results

Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting

Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference

New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy

Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer

New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte's Genomic Tests in Interstitial Lung Disease and Lung Cancer

Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022

Due to the downturn in the broader market, this genetic-testing stock has crashed so far this year.

Should Growth Investors Buy This Little-Known Stock?

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced that new data from a Phase 3 trial of the multi-center, multi-national, randomized STAMPEDE platform protocol confirm the ability of the company's Decipher Prostate Genomic Classifier to identify men with advanced prostate cancer who are more likely to benefit from intensified treatment with abiraterone acetate and prednisolone (AAP) in addition to standard-of-care androgen-deprivation therapy (Abstract #13580

New Data Presented at ESMO 2022 Show Veracyte's Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), are likely to have progressive disease that declines with combination immunosuppressive therapy. These findings, shared at the European Respiratory Society (ERS) International Congress 2022 (Abstract #PA1948), are important beca

New Data Suggest Veracyte's Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that Marc Stapley, chief executive officer, and Rebecca Chambers, chief financial officer, will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, at 2:55 p.m. Eastern Time. A live audio webcast of the company's presentation will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay o

Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that seven abstracts showcasing the company's genomic tests for prostate (Decipher) and breast (Prosigna) cancers will be presented at the European Society for Medical Oncology (ESMO) Congress 2022, taking place September 9-13, 2022, in Paris. “The abstracts we'll share at ESMO 2022 reinforce the value our genomic tests bring to physicians diagnosing and treating cancer patients,” said Marc Stapley, Vera

Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--New data published in Nature Medicine suggest Veracyte's immuno-oncology biomarkers could help predict patient response to immunotherapies.

New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma

News for Veracyte Stock (VCYT)